Renhaim Therapeutics develops RNA-based biopharmaceuticals, focusing on cancer vaccines and gene cell therapies tailored to patient needs. By collaborating with specialized research firms, the company aims to efficiently advance drug development from bench research to market approval.
Funding
Funding not disclosed
Founders
Product
Problem
Developing gene and cell therapies, as well as cancer vaccines, requires specialized expertise and resources across various stages, from initial research to clinical trials and regulatory approval. The complexity and resource intensity of this process can be a significant burden for individual biotechnology companies.
Solution
Renhaim Therapeutics is a biotechnology company focused on developing genome-based therapeutics, including cancer vaccines and gene and cell therapies, through strategic partnerships. The company employs an open innovation model, collaborating with specialized research organizations to streamline the drug development process. This approach allows Renhaim to leverage external expertise and resources, accelerating the transition of promising therapies from the laboratory to the market.
Target Audience
Renhaim Therapeutics targets patients in need of advanced therapies for cancer and other diseases treatable with gene and cell therapies.
Features
- Focus on RNA-based biopharmaceuticals, including cancer vaccines and gene and cell therapies.
- Strategic partnerships with specialized research firms to enhance R&D capabilities.
- Open innovation model to leverage external expertise and resources.
- Development of therapeutics tailored to individual patient needs.
- Streamlined drug development process from bench research to market approval.